SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the requirements for a robust ICB response is incomplet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibáñez-Molero, Sofía, van Vliet, Alex, Pozniak, Joanna, Hummelink, Karlijn, Terry, Alexandra M., Monkhorst, Kim, Sanders, Joyce, Hofland, Ingrid, Landeloos, Ewout, Van Herck, Yannick, Bechter, Oliver, Kuilman, Thomas, Zhong, Weiwei, Marine, Jean-Christophe, Wessels, Lodewyk, Peeper, Daniel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710519/
https://www.ncbi.nlm.nih.gov/pubmed/36465485
http://dx.doi.org/10.1080/2162402X.2022.2139074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710519/
https://www.ncbi.nlm.nih.gov/pubmed/36465485
http://dx.doi.org/10.1080/2162402X.2022.2139074

Ejemplares similares